Akero Non Currrent Assets Other from 2010 to 2024
| AKRO Stock | USD 23.98 0.64 2.60% |
Non Currrent Assets Other | First Reported 2010-12-31 | Previous Quarter (1.00) | Current Value (0.95) | Quarterly Volatility 107.7 K |
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 3.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
Akero | Non Currrent Assets Other |
Latest Akero Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Akero Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Akero Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Akero Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 59,667 | |
| Geometric Mean | 8,590 | |
| Coefficient Of Variation | 180.57 | |
| Mean Deviation | 67,600 | |
| Median | 20,000 | |
| Standard Deviation | 107,741 | |
| Sample Variance | 11.6B | |
| Range | 417K | |
| R-Value | 0.33 | |
| Mean Square Error | 11.2B | |
| R-Squared | 0.11 | |
| Significance | 0.23 | |
| Slope | 7,889 | |
| Total Sum of Squares | 162.5B |
Akero Non Currrent Assets Other History
About Akero Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Akero Therapeutics income statement, its balance sheet, and the statement of cash flows. Akero Therapeutics investors use historical funamental indicators, such as Akero Therapeutics's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Akero Therapeutics investors may use each financial statement separately, they are all related. The changes in Akero Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Akero Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Akero Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Akero Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | (1.00) | (0.95) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Akero Stock
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:Check out the analysis of Akero Therapeutics Correlation against competitors. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.